Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 2/2020

Open Access 01-02-2020 | Osteoporosis | Original Article

Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data

Authors: L. Cui, T. He, Y. Jiang, M. Li, O. Wang, R. Jiajue, Y. Chi, Q. Xu, X. Xing, W. Xia

Published in: Osteoporosis International | Issue 2/2020

Login to get access

Abstract

Summary

This study built a micro-simulation Markov model to determine the treatment threshold of osteoporosis in postmenopausal women in Mainland China. Treatment with zoledronate is cost-effective when FRAX-based (Fracture risk assessment tool) fracture probability is over 7%.

Introduction

The purpose of this study is to estimate FRAX-based fracture probabilities in Mainland China using real-world data, at which intervention could be cost-effective.

Methods

We developed a micro-simulation Markov model to capture osteoporosis states and relevant morbidities including hip fracture, vertebral fracture, and wrist fracture. Baseline characteristics including incidences of osteoporosis and distribution of risk factors were derived from the Peking Vertebral Fracture study, the largest prospective cohort study of postmenopausal women in Mainland China. We projected incidences of fractures and deaths by age groups under two treatment scenarios: 1) no treatment, and 2) zoledronate. We also projected total quality-adjusted life-years (QALY) and total costs including fracture management and osteoporosis drugs for cost-effectiveness analysis. Cost-effective intervention thresholds were calculated based on the Chinese FRAX model.

Results

Treatment with zoledronate was cost-effective when the 10-year probability of major osteoporotic fracture based on FRAX was above 7%. The FRAX threshold increased by age from 51 to 65 years old, and decreased in elder age groups, ranging from 4% to 9%.

Conclusions

Using real-world data, our model indicated that widespread use of zoledronate was of both clinical and economic benefit among Chinese postmenopausal women. Using a FRAX-based intervention threshold of 7% with zoledronate should permit cost-effective access to therapy to patients and contribute to reducing the disease burden of osteoporosis in Mainland China.
Appendix
Available only for authorised users
Literature
1.
Chinese health promotion fundation editorial board of Chinese White Papers of osteoporosis (2009) Chinese White Papers of osteoporosis. Chin J Health Manag 3:148–154
2.
Cui L, Chen L, Xia W et al (2017) Vertebral fracture in postmenopausal Chinese women: a population-based study. Osteoporos Int 28:2583–2590PubMedCrossRef
3.
Si L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ (2015) Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int 26:1929–1937PubMedCrossRef
4.
Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15PubMedCrossRef
5.
Chinese Medical Association the Branch of Osteoporosis and Bone Mineral Disease (2017) Guideline of diagnosis and treatment of primary osteoporosis. Chin J Osteoporos Bone Miner Res 10:413–444
6.
7.
Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408PubMedCrossRef
8.
Lippuner K, Johansson H, Borgstrom F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int 23:2579–2589PubMedCrossRef
9.
Makras P, Athanasakis K, Boubouchairopoulou N, Rizou S, Anastasilakis AD, Kyriopoulos J, Lyritis GP (2015) Cost-effective osteoporosis treatment thresholds in Greece. Osteoporos Int 26:1949–1957PubMedCrossRef
10.
Marques A, Lourenco O, Ortsater G, Borgstrom F, Kanis JA, da Silva JA (2016) Cost-effectiveness of intervention thresholds for the treatment of osteoporosis based on FRAX((R)) in Portugal. Calcif Tissue Int 99:131–141PubMedCrossRef
11.
Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197PubMedCrossRef
12.
Cheung E, Cheung CL, Kung AW, Tan KC (2014) Possible FRAX-based intervention thresholds for a cohort of Chinese postmenopausal women. Osteoporos Int 25:1017–1023PubMedCrossRef
13.
Chang AJ, Ying Q, Chen XN, Wang WM, Chen N (2016) Evaluation of three risk assessment tools in discriminating fracture status among Chinese patients undergoing hemodialysis. Osteoporos Int 27:3599–3606PubMedCrossRef
14.
Cheung EY, Bow CH, Cheung CL, Soong C, Yeung S, Loong C, Kung A (2012) Discriminative value of FRAX for fracture prediction in a cohort of Chinese postmenopausal women. Osteoporos Int 23:871–878PubMedCrossRef
15.
Zhao J, Xia W, Nie M et al (2012) A haplotype of MATN3 is associated with vertebral fracture in Chinese postmenopausal women: Peking Vertebral Fracture (PK-VF) study. Bone 50:917–924PubMedPubMedCentralCrossRef
16.
Li N, Wang X, Jiang Y et al (2014) Association of GALNT3 gene polymorphisms with bone mineral density in Chinese postmenopausal women: the Peking Vertebral Fracture study. Menopause 21:515–521PubMedCrossRef
17.
Zhao J, Xia W, Nie M et al (2011) The levels of bone turnover markers in Chinese postmenopausal women: Peking Vertebral Fracture study. Menopause 18:1237–1243PubMedCrossRef
18.
Bow CH, Cheung E, Cheung CL et al (2012) Ethnic difference of clinical vertebral fracture risk. Osteoporos Int 23:879–885PubMedCrossRef
19.
Wang J, Wang Y, Liu WD, Wang F, Yin ZS (2014) Hip fractures in Hefei, China: the Hefei osteoporosis project. J Bone Miner Metab 32:206–214PubMedCrossRef
20.
Lofthus CM, Frihagen F, Meyer HE, Nordsletten L, Melhuus K, Falch JA (2008) Epidemiology of distal forearm fractures in Oslo, Norway. Osteoporos Int 19:781–786PubMedCrossRef
21.
Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23PubMedCrossRef
22.
Kanis J, Brazier J, Stevenson M, Calvert N, Lloyd Jones M (2003) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:146
23.
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521PubMedCrossRef
24.
Sun S, Chen J, Johannesson M, Kind P, Xu L, Zhang Y, Burstrom K (2011) Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res 20:309–320PubMedCrossRef
25.
Si L, Winzenberg TM, de Graaff B, Palmer AJ (2014) A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporos Int 25:1987–1997PubMedCrossRef
26.
Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef
27.
Tremblay E, Perreault S, Dorais M (2016) Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos 11:30PubMedCrossRef
28.
29.
China Center for Health Economic Research (2011) China Guidelines for Pharmacoeconomic Evaluations. Beijing.
30.
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47PubMedCrossRef
31.
Qu B, Ma Y, Yan M, Wu HH, Fan L, Liao DF, Pan XM, Hong Z (2014) The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int 25:1853–1860PubMedCrossRef
32.
33.
National Bureau of Statistics (2016) Status of deaths by age and sex (2011.11.1-2012.10.30). 2012 National Sample Survey on Population Changes. China Statistics Press
34.
Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA (2011) Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 155:827–838PubMedCrossRef
35.
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev Cd001155
36.
Nayak S, Roberts MS, Greenspan SL (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 155:751–761PubMedPubMedCentralCrossRef
37.
Cheng TT, Yu SF, Hsu CY, Chen SH, Su BY, Yang TS (2013) Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines. Clin Ther 35:1005–1015PubMedCrossRef
38.
Cheng XG, Yang DZ, Zhou Q et al (2007) Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database of women at multiple centers in China. J Clin Densitom 10:276–284PubMedCrossRef
39.
Park C, Ha YC, Jang S, Jang S, Yoon HK, Lee YK (2011) The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab 29:744–751PubMedCrossRef
40.
41.
Chinese medical associaton branch of osteoporosis and bone mineral disease (2017) Guideline of prevention and treatment of primary osteoporosis. Chin J Osteoporos Bone Miner Res 10:413–443
42.
Jiang Y, Ni W (2016) Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX. J Bone Miner Metab 34:714–722PubMedCrossRef
43.
Ni W, Jiang Y (2017) Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model. Osteoporos Int 28:529–538PubMedCrossRef
44.
Si L, Winzenberg TM, Chen M, Jiang Q, Neil A, Palmer AJ (2016) Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study. Osteoporos Int 27:2259–2269PubMedCrossRef
45.
Si L, Winzenberg TM, Jiang Q, Palmer AJ (2015) Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model. Osteoporos Int 26:1477–1489PubMedCrossRef
46.
Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedPubMedCentralCrossRef
47.
Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443PubMedCrossRef
48.
Liu GG, Wu H, Li M, Gao C, Luo N (2014) Chinese time trade-off values for EQ-5D health states. Value Health 17:597–604PubMedCrossRef
49.
Hiligsmann M, Reginster JY, Tosteson ANA et al (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30:45–57PubMedCrossRef
50.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics 31:361–367PubMedCrossRef
Metadata
Title
Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data
Authors
L. Cui
T. He
Y. Jiang
M. Li
O. Wang
R. Jiajue
Y. Chi
Q. Xu
X. Xing
W. Xia
Publication date
01-02-2020
Publisher
Springer London
Published in
Osteoporosis International / Issue 2/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-05173-6

Other articles of this Issue 2/2020

Osteoporosis International 2/2020 Go to the issue

Original Article

Relationship between bone mineral content and bone turnover markers, sex hormones and calciotropic hormones in pre- and early pubertal children

Original Article

The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: a meta-analysis

Original Article

Association between vertebral fractures and coronary artery calcification in current and former smokers in the ECLIPSE cohort

Original Article

Multiple simultaneous fractures are associated with higher all-cause mortality: results from a province-wide fracture liaison service

Review

Rib fractures after blunt thoracic trauma in patients with normal versus diminished bone mineral density: a retrospective cohort study

Original Article

The Nottingham Spinal Health (NoSH) Study: a cohort study of patients hospitalised with vertebral fragility fractures